Use of once-weekly semaglutide more than doubles the risk for nonarteritic anterior ischemic optic neuropathy (NAION) in ...

Semaglutide exposure was significantly associated with a higher incidence rate and independently predicted a higher risk for upcoming nonarteritic anterior ischemic optic neuropathy, even when ...

Findings were seen for patients with type 2 diabetes during a 5-year period. HealthDay News — Use of once-weekly semaglutide more than doubles the risk for nonarteritic anterior ischemic optic ...

Semaglutide is associated with nonarteritic anterior ischemic optic neuropathy (NAION) among patients with type 2 diabetes (T2D) and those with overweight/obesity.

Semaglutide exposure was significantly associated with a higher incidence rate and independently predicted a higher risk for upcoming nonarteritic anterior ischemic optic neuropathy. HealthDay ...

Findings seen for patients with type 2 diabetes during a 5-year period. (HealthDay News) — Use of once-weekly semaglutide more than doubles the risk for nonarteritic anterior ischemic optic ...

(HealthDay News) — Use of once-weekly semaglutide more than doubles the risk for nonarteritic anterior ischemic optic neuropathy (NAION) in individuals with type 2 diabetes, according to a study ...

TUESDAY, Jan. 14, 2025 (HealthDay News) — Use of once-weekly semaglutide more than doubles the risk for nonarteritic anterior ischemic optic neuropathy (NAION) in individuals with type 2 diabetes, ...